Get the Stockscreener App
1.20
3.45%
0.04
After Hours:
1.14
-0.06
-5.00%
Gossamer Bio Inc stock is traded at $1.20, with a volume of 1.93M.
It is up +3.45% in the last 24 hours and up +34.11% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
See More
Previous Close:
$1.16
Open:
$1.12
24h Volume:
1.93M
Relative Volume:
1.19
Market Cap:
$272.76M
Revenue:
-
Net Income/Loss:
$-179.82M
P/E Ratio:
-0.9023
EPS:
-1.33
Net Cash Flow:
$-159.16M
1W Performance:
+15.38%
1M Performance:
+34.11%
6M Performance:
+72.51%
1Y Performance:
+88.44%
1-Day Range:
$1.12
$1.21
1-Week Range:
$1.03
$1.23
52-Week Range:
$0.4993
$1.55
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
1.20 | 236.39M | 0 | -179.82M | -159.16M | -1.33 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
Cantor Fitzgerald Forecasts Gossamer Bio FY2025 Earnings - Defense World
Analyze Gossamer Bio Inc (NASDAQ: GOSS) Before Investing. - Stocksregister
Price T Rowe Associates Inc. MD Has $59,000 Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2025 Earnings Call Transcript - MSN
Wedbush Reiterates “Outperform” Rating for Gossamer Bio (NASDAQ:GOSS) - Defense World
The Goldman Sachs Group Raises Gossamer Bio (NASDAQ:GOSS) Price Target to $8.00 - Defense World
GOSS Stock Update: Analyst Reiterates Outperform Rating | GOSS S - GuruFocus
Gossamer Bio’s Earnings Call: Mixed Sentiments and Strategic Moves - TipRanks
Gossamer Bio (GOSS): Goldman Sachs Raises Price Target to $8.00 - GuruFocus
Cantor Fitzgerald maintains Overweight on Gossamer Bio stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald maintains Overweight on Gossamer Bio stock - Investing.com
Earnings call transcript: Gossamer Bio exceeds Q1 2025 revenue forecasts By Investing.com - Investing.com Nigeria
Gossamer Bio: Q1 Earnings Snapshot - CT Insider
Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strategic Progress Amid Financial ... - Yahoo Finance
Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strate - GuruFocus
Transcript : Gossamer Bio, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Earnings call transcript: Gossamer Bio exceeds Q1 2025 revenue forecasts - Investing.com Australia
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Gossamer Bio earnings beat by $0.03, revenue topped estimates - Investing.com
Gossamer Bio Inc (GOSS) Q1 2025 Earnings: EPS Loss of $0.16 Beats Estimate, Revenue Surges to $9.9 Million - GuruFocus
GOSSAMER BIO Earnings Results: $GOSS Reports Quarterly Earnings - Nasdaq
Gossamer Bio (GOSS) Surpasses Revenue Estimates, Advances Key St - GuruFocus
Gossamer Bio (GOSS) Surpasses Revenue Estimates, Advances Key Studies | GOSS Stock News - GuruFocus
Gossamer Bio, Inc. SEC 10-Q Report - TradingView
Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study - Eagle-Tribune
Gossamer Bio Q1 2025 Earnings Call Transcript - MarketBeat
What To Expect From Gossamer Bio Inc (GOSS) Q1 2025 Earnings - GuruFocus
Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025 - Eagle-Tribune
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 7, 2025 - BioSpace
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rul - GuruFocus
Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference - The Joplin Globe
Market Highlights: Gossamer Bio Inc (GOSS) Ends on a Low Note at 1.09 - DWinneX
Gossamer Bio Inc: Is GOSS Stock Worth Buying? - Stocksregister
Gossamer Bio (GOSS) Expected to Announce Earnings on Tuesday - Defense World
Gossamer Bio: Initiating Hold As Late‐Stage Data Nears Inflection (GOSS) - Seeking Alpha
Selling Buzz: Gossamer Bio Inc [GOSS] Chief Medical Officer Aranda Richard sells 1,908 shares of the company - knoxdaily.com
Check out these key findings about Gossamer Bio Inc (GOSS) - Sete News
Geode Capital Management LLC Has $2.04 Million Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Was Gossamer Bio Inc (GOSS)’s session last reading good? - uspostnews.com
Gossamer Bio Inc (GOSS) Stock: A Year of Declines and Increases - investchronicle.com
Closing Strong: Gossamer Bio Inc (GOSS) Ends at 1.17, Up 0.86 from Last Close - DWinneX
Monitoring Gossamer Bio Inc (GOSS) after recent insider movements - knoxdaily.com
Gossamer Bio Inc (GOSS Stock: A Sea of Opportunity - investchronicle.com
Gossamer Bio Insider Confidence Rewarded, Stock Hits US$203m Market Cap - simplywall.st
3 Promising Penny Stocks With Market Caps Over $100M - simplywall.st
Taking the lead: Gossamer Bio Inc (GOSS) - Sete News
Oppenheimer initates Gossamer Bio Inc (GOSS) rating to an Outperform - knoxdaily.com
GOSS’s price-to-cash ratio: Is it a good investment at the moment? - uspostnews.com
Stock Performance Spotlight: Gossamer Bio Inc (GOSS) Ends the Day at 0.83, Up by 1.77 - DWinneX
Pleasing Signs As A Number Of Insiders Buy Gossamer Bio Stock - Yahoo Finance
The Goldman Sachs Group Has Lowered Expectations for Gossamer Bio (NASDAQ:GOSS) Stock Price - Defense World
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
17.27%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):